Research programme: antibody-based therapeutics - BioAtla

Drug Profile

Research programme: antibody-based therapeutics - BioAtla

Alternative Names: CAB anti-AXL ADC; CAB-ADC; CAB-Axl antibodies; CAB-Axl antibody-drug conjugates; CAB-Axl-ADC

Latest Information Update: 30 Apr 2016

Price : $50

At a glance

  • Originator BioAtla
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Axl receptor tyrosine kinase inhibitors; Cytokine inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer; Colorectal cancer; Crohn's disease; Haematological malignancies; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Ulcerative colitis

Most Recent Events

  • 16 Apr 2016 Preclinical trials in Cancer in USA (Parenteral) before April 2016
  • 14 Apr 2016 Pharmacodynamics and adverse events data from preclincial studies in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 11 Jun 2015 Research programme: antibody-based therapeutics - BioAtla is available for licensing in China as of 11 Jun 2015. http://bioatla.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top